Author(s):
Khatri Upasana, Kamal Singh Rathore, Sunil Saini, Bharkatiya Meenakshi
Email(s):
upasana.khatriupasana.khatri@gmail.com
DOI:
10.5958/0974-360X.2020.00455.2 
Address:
Khatri Upasana1*, Kamal Singh Rathore2, Sunil Saini1, Bharkatiya Meenakshi2
1Assistant Professor, Maulana Azad University, Pharmacy Wing, Jodhpur Raj India 342802.
2Associate Professor, BN Institute of Pharmaceutical Science, BN University, Udaipur Raj India 313001.
*Corresponding Author
Published In:
Volume - 13,
Issue - 6,
Year - 2020
ABSTRACT:
Objective: In the present dissertation work, the aim was to prepare nasal in-situ gel of ketorolac tromethamine, a potent non-narcotic analgesic with moderate anti-inflammatory activity to improve its retention time by making sustain release dosage form and also avoid first pass metabolism of drug. Method: The prepared gel was the concentrate of drug, Carbopol polymer (cross linking gelling agent), HPMC as thickening agent or viscosity enhancing agent and buffering agent. The formulation was evaluated for various tests such as solubility, pH determination, rheological studies using Brookfield viscometer, gelling capacity, drug content, Mucoadhesive strength, gel strength, in-vitro release study and kinetic treatment of release data. Result: The optimized formulation F6 showed pH (6.4+0.10), drug release at 360min (79.86+0.64) , drug content (109.965+0.044), viscosity at 20 rpm at pH 4 and pH 6.4 (293+1.00) (3115+1.00) respectively, Mucoadhesive strength (3763±1.37), gelling capacity (51±0.39). In vitro drug release of the F6 was highly significant (p<0.05) as compare to the other formulation. Conclusion: Ketorolac tromethamine was successfully formulated in pH triggered in-situ gelling system using Carbopol 934 in combination with HPMC K4M. It was seen that HPMC K4M is important for in-situ gel behaviour along with Carbopol 934 on the basis of main effect of concentration of HPMC K4M and Carbopol 934. In-vitro results indicated that the in-situ gel system is a viable alternative to conventional nasal drops by virtue of its ability to sustain drug release.
Cite this article:
Khatri Upasana, Kamal Singh Rathore, Sunil Saini, Bharkatiya Meenakshi. Formulation and Evaluation of Ketorolac Tromethamine using 32 Factorial Design. Research J. Pharm. and Tech 2020; 13(6)2556-2562. doi: 10.5958/0974-360X.2020.00455.2
Cite(Electronic):
Khatri Upasana, Kamal Singh Rathore, Sunil Saini, Bharkatiya Meenakshi. Formulation and Evaluation of Ketorolac Tromethamine using 32 Factorial Design. Research J. Pharm. and Tech 2020; 13(6)2556-2562. doi: 10.5958/0974-360X.2020.00455.2 Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-6-5
REFERENCES:
1. Ennam SJ, David B Bylund, N. “X Pharma the Comprehe Book” 2008:8,514-8,578.
2. V Sanjay Dey, et al., “Nasal Drug Delivery: An Approach of drug delivery through Nasal Route”, Pelagia Research Library, 2011, 2(3): 94-106.
3. Li X, et al. “Nasal delivery of analgesic ketorolac tromethamine thermo- and ion-sensitive in-situ hydrogels” International Journal of Pharmaceutics, 2015, 489(1-2): 252-260.
4. Khatri Upasana, Saini Sunil, Rathore Kamal S. Recent Overview on Nasal In-situ Gel. International Journal of Medical and Pharmaceutical Sciences, 2017, 3(2), 14-21.
5. Illum L, “Nasal Drug Delivery: New Developments and Strategies.” Drug Discovery Today, 2002, 7: 1184–1189.
6. Varma MV, et al., “Physicochemical Space for Optimum Oral Bioavailability: Contribution of Human Intestinal Absorption and First-Pass Elimination” Journal of Medicinal Chemistry, 2010, 53: 1098–1108.
7. Illum L, et al., “Nasal Drug Delivery-Possibilities, Problems and Solutions” Journal of Controlled release, 2003, 87: 187–198.
8. Raymond CR, et al., “Handbook of Pharmaceutical Excipients” Published by the Pharmaceutical Press and the American Pharmacists Association NW, Washington DC, USA, 2009, 6: 110-114.
9. YW Chien, et al., “A text book of Anatomy and physiology of the nose. In Nasal Systemic Drug Delivery: Drugs and the Pharmaceutical Sciences.” New York, Marcel Decker: 1989.
10. Bechgaard E, et al., “BioPharma and Drug Disposal” 1982; 3: 337-344.
11. Tahani H, et al. Journal of Controlled release; 1994, 32: 279-283.
12. Cho E, et al. “In-situ gelling and Mucoadhesive lquid suppository containing acetaminophen enhanced bioavailability” International Journal of Pharmaceutics 1998, 165: 23-32.
13. Dondeti P, Zia H. “Bioadhesive and formulation parameter affecting nasal absorption” International Journal of Pharmaceutics, 1996, 127: 115-133.
14. Mehta MR, Surve SA et al., “In situ nasal drug delivery system-a review”. International Journal of Pharmaceutics sciences. 2010, 59: 153-180.
15. Talasahaz AHH, Ali A. Journal of Applied Polymer Science. 2008, 109: 2369-2374.
16. Nakamura F, Ohta R, Machida Y, Nagai T. International Journal of Pharmaceutics, 134, 173-181(1996).
17. Pawar Piyush, et al., “Formulation and Evaluation of in-Situ Nasal Gel of Ramipril” International Journal of Institutional Pharmacy and Life Sciences, 2015, 5(4): 67-78.
18. Yadav J, et al. “Formulation and Evaluation of Thermosensitive in Situ Gel of Salbutamol Sulphate for Nasal Drug Delivery System: International Journal of Pharmacy and Pharmaceutical Sciences”. 2012:57-68.
19. Farnes et al. “Ketorolac trometamine compositions for treating ocular pain”. United States Patent 7,842,714; 2010.